Artelo Biosciences
ARTL
6 hedge funds and large institutions have $152K invested in Artelo Biosciences in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more funds holding
Funds holding: 3 → 6 (+3)
1.4% less ownership
Funds ownership: 3.03% → 1.64% (-1.4%)
31% less capital invested
Capital invested by funds: $220K → $152K (-$68.5K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$175K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$143K |
| 3 |
Morgan Stanley
New York
|
+$11.3K |
| 4 |
Citigroup
New York
|
+$4.96K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$213K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.93K |
| 3 |
DB
Danske Bank
Copenhagen K,
Denmark
|
-$13 |
ARTL Hedge Fund Activity: Q3 2025 in Review
6 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2025, worth a combined $152K — down 31% from $220K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ARTL positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $175K. The largest seller was Geode Capital Management, exiting entirely with an estimated $213K sold.
- 6 institutional investors held Artelo Biosciences (ARTL) as of Q3 2025, up from 3 in Q2 2025.
- Funds reported $152K of Artelo Biosciences stock for Q3 2025, down 31% quarter-over-quarter.
- 5 funds opened new Artelo Biosciences positions in Q3 2025 and 2 closed out, a net change of +3 holders.
- The largest Artelo Biosciences buyer in Q3 2025 was DRW Securities, an estimated $175K added.
- The largest Artelo Biosciences seller in Q3 2025 was Geode Capital Management, an estimated $213K sold.
Based on aggregated 13F filings for Q3 2025.